QIAGEN N.V. [NYSE: QGEN] revealed that it has obtained EUA from FDA for NeuMoDx Flu A-B/RSV/SARS-CoV-2. NeuMoDx will assist health-care experts in rapidly recognize and distinguish between individuals alleged by the healthcare supplier of respiratory viral infection along with COVID-19.
Currently, the restrictions and social distancing precautions are decreased all around the globe. It will aggravate the chances of respiratory viral diseases. Furthermore, it has been disclosed that medical indicators of respiratory viral infection due to SARS-CoV-2, influenza, or RSV can be alike. Because of this, it is necessary to recognize the patients who have got the infection.
QGEN rolled out the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test in the EU and other markets that endorsed CE-IVD in November 2020 and will now commence marketing of the test in the U.S. The new respiratory test of QGEN leverage the mechanized three-step system of NeuMoDx 96 & NeuMoDx 288 molecular systems.
After approval from the FDA, it is now easy to distinguish between the SARS-CoV-2 infection and other viral diseases. This test is the need of the time. QGEN completely bought NeuMoDx in September 2020 and declared it one of its five growth accelerators for the firm to proceed rising on a separate basis.